|
|
Volumn 3, Issue 10, 2011, Pages 1247-1252
|
|
The TB Alliance: overcoming challenges to chart the future course of TB drug development.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 NITRO 6 (4 (TRIFLUOROMETHOXY)BENZYLOXY) 6,7 DIHYDRO 5H IMIDAZO(2,1 B)(1,3)OXAZINE;
2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE;
BEDAQUILINE;
HETEROCYCLIC COMPOUND;
MOXIFLOXACIN;
NITROIMIDAZOLE DERIVATIVE;
QUINOLINE DERIVATIVE;
TUBERCULOSTATIC AGENT;
ARTICLE;
CHEMISTRY;
CLINICAL TRIAL (TOPIC);
DRUG SCREENING;
HUMAN;
NONBIOLOGICAL MODEL;
TUBERCULOSIS;
ANTITUBERCULAR AGENTS;
AZA COMPOUNDS;
CLINICAL TRIALS AS TOPIC;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
MODELS, ORGANIZATIONAL;
NITROIMIDAZOLES;
QUINOLINES;
TUBERCULOSIS;
|
|
EID: 84856378024
PISSN: None
EISSN: 17568927
Source Type: Journal
DOI: 10.4155/fmc.11.82 Document Type: Article |
|
Times cited : (24)
|
|
References (0)
|
